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Abstract
Aim: This randomized, controlled trial examined the medium-term effectiveness of online behavioral training in migraine
self-management (oBT; N¼ 195) versus waitlist control (WLC; N¼ 173) on attack frequency, indicators of self-manage-
ment (primary outcomes), headache top intensity, use of rescue medications, quality of life and disability (secondary
outcomes).
Methods: An online headache diary following the ICHD-II and questionnaires were completed at baseline (T0), post-
training (T1) and six months later (T2). Missing data (T1: 24%; T2: 37%) were handled by multiple imputation. We
established effect sizes (ES) and tested between-group differences over time with linear mixed modelling techniques
based on the intention-to-treat principle.
Results: At T2, attack frequency had improved significantly in oBT (23%, ES¼ 0.66) but also in WLC (19%; ES¼ 0.52).
Self-efficacy, internal and external control in migraine management – and triptan use – improved only in oBT, however.
This indicates different processes in both groups and could signify (the start of) active self-management in oBT. Also, only
oBT improved migraine-specific quality of life to a sizable extent.
Conclusions: oBT produced self-management gains but could not account for improved attack frequency, because WLC
improved as well. The perspective that BT effects develop gradually, and that online delivery will boost BT outreach,
justifies further research.
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Introduction
Migraine attacks of pounding headache impede work
performance and family or social life (1) and are the
seventh disabler worldwide according to the World
Health Organization (WHO) Global Burden of Disease
Survey 2010 (2). Early treatment of the pain is more
eﬀective than waiting until the attack is fully developed
(3), and attack prevention and proactive migraine man-
agement are gaining increasing emphasis (3–5).
Behavioral training (BT) pursues proactive manage-
ment and is advocated in neurological guidelines as a
supplementary preventive treatment (6). A ﬁrst focus of
BT is on anticipating attacks by the timely recognition
of premonitory symptoms. Because the prodromal
stage of the attack is badly demarcated, this task is
neither plain nor easy. Electronic diaries pointed at
the relevance of the last 12 hours before attack onset
when distinct symptoms emerge (7) and attacks are
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predicted relatively well (8). This substantiates the aim
that early symptom detection is possible and could be
learned (3). A second focus of BT is on self-regulation
skills through relaxation training and cognitive-
behavioral intervention (9). BT is targeted at increasing
perceived control over migraine, reducing attack fre-
quency and intensity, and decreasing migraine-speciﬁc
disability (9,10).
Clinic-based BT can reduce attack occurrence by
35%–55% (11), but this form of BT is scarcely avail-
able. To increase BT access and engage patients more in
self-management, we involved trained patient trainers
who oﬀered BT at home (12–14). The lay trainers were
well received (14), and BT yielded strong and stable
improvements in migraine self-eﬃcacy and perceived
control (12,13). Yet, improved attack frequency post
BT (21%) did not reach signiﬁcance (p¼ 0.07) com-
pared to waitlist control (WLC) (6%) (13), while we
found signiﬁcant attack improvement six months later
(23%; p< 0.000) in an uncontrolled study (13).
Importantly, all outcomes were maintained for three
years on average (15).
Since the Internet ampliﬁes the promise of BT out-
reach (16), we converted the former BT protocol (12,13)
to an Internet application delivered with minimal guid-
ance, and we extended the eﬀectiveness trial of online
BT (oBT) versus WLC up to six months after post-
treatment (e.g. 10 months after baseline). Most prior
studies in oBT (17–23) were conﬁned to post-training
measurement (17–20,22) four of which yielded signiﬁ-
cant headache improvement (17,19,20,22) also com-
pared to WLC (17,19) or active control (22).
Unfortunately the comparison with two recent oBT
studies with control over six months post-training is
limited given diﬀerences in study group (youngsters
aged 12 years on average) (21) and the exclusion of
headache as an outcome variable (23).
The oBT post-training eﬀects are reported elsewhere
(24) and closely matched those of BT oﬀered by patient
trainers (12), but attack frequency improved in WLC as
well (24). However, compared to WLC, oBT yielded
positive change in self-eﬃcacy and perceived control
indicating improved self-management. Since BT has a
longer time to beneﬁts than drugs (25), this study aims
to establish oBT eﬀectiveness relative to WLC for six
months post-treatment regarding the parameters
employed in the study with patient trainers (12–15).
The question is whether oBT improves attack fre-
quency and migraine self-eﬃcacy and locus of control
(LOC) over time (primary outcomes) as well as
migraine-speciﬁc quality of life and disability (second-
ary outcomes). Eﬀects over time were also tested for
headache top intensity and use of rescue medications
(secondary outcomes). Among the explorative analyses
we examined whether attack improvement while on the
waitlist resulted from consuming other health care, or
from using the online migraine monitor provided in this
study (24).
Methods
Design
We conducted a randomized, controlled trial to estab-
lish oBT eﬀectiveness relative to WLC up to 10 months
after baseline (T0), with assessments post-training (T1)
and six months later (T2). The average completion time
of the study was 11.6 months in oBT (SD¼ 1.7) and
11.1 months in WLC (SD¼ 0.5).
Participants
Participants were recruited through referral of the
Dutch Headache Centers (www.hoofdpijncentra.nl)
(26%) and the website of the Dutch Society of
Headache Patients (www.hoofdpijnpatienten.nl)
(21%); the remaining participants enlisted mostly in
response to ﬂyers in general practitioner (GP) oﬃces.
The inclusion criteria were (1) an age of 18 to 65
years, (2) migraine according to the International
Classiﬁcation of Headache Disorders, second edition
(ICHD-II) criteria (International Classiﬁcation of
Diseases (ICD)-10NA; migraine without (G43.0) or
with (G43.1) aura) (26)), (3) two to six migraine attacks
in the month prior to randomization. The exclusion
criteria were (1) headache occurring on more than 15
days or (2) medication overuse (10 triptans, or anal-
gesics on 15 days) in the month before randomization,
(3) a score 178 on the Symptom Checklist (SCL)-90R
screening instrument for psychopathology, (4) migraine
onset in the previous year, (5) current or planned
pregnancy.
Procedure
The study was approved by the Medical Ethics
Committee of the University Medical Centre Utrecht
(no. 10-304). Eligibility was assessed in the study’s pro-
tected web-portal (www.mymigraine.nl) where ques-
tionnaires (ID MigraineTM SCL-90R) were completed
and a prospective headache diary designed according to
trial guidelines (8,27) was kept.
Eligible participants signed for informed consent,
completed the T0 measures and were assigned with
equal probability to either the oBT or WLC condition
(unrestricted randomization based on a computerized
scheme) by a research assistant who was unaware of the
next group allocation; blinding was not possible since
the study concerned a psychological intervention (8).
Non-eligible patients were advised of and received
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contact information of a nearby headache center if
desired. Psychosocial help was suggested in case of
problems indicated by the SCL-90R. Although this
was allowed, participants were kindly requested not
to change their medication or start other treatments
during the study.
Intervention
oBT aims at attack prevention. It incorporates training
in relaxation and cognitive behavioral techniques
attested with grade-A for non-pharmacological
migraine prophylaxis (5) and includes 70% of estab-
lished behavioral change techniques (BCTs) advocated
for web-based interventions (28). (Important BCTs per-
tain to graded tasks, speciﬁc goal setting and review of
behavioral goals; behavior self-monitoring with teach-
ing the use of prompts and cues, feedback on perform-
ance and barrier identiﬁcation; behavioral modeling
and social comparison, a focus on time- or stress-man-
agement, and relapse prevention.) It was closely
adopted from the manual formerly used by patient trai-
ners (12–15), which in turn was grafted on a cognitive
behavioral therapy protocol for headache (29). oBT
consists of eight lessons oﬀered with voiceover, four
relaxation audios, 26 videos of exemplary patients,
interactive exercises, homework, and email support
(30). Each lesson pursues two steps under the catch-
words ‘‘face your migraine’’ and ‘‘ease your migraine.’’
‘‘Face your migraine’’ subsumes exercises to detect pat-
terns of premonitory symptoms and triggers of the
attack well before the headache strikes. ‘‘Ease your
migraine’’ incorporates techniques for physical relax-
ation and cognitive-behavioral self-regulation (priority
setting, time management, reshaping of involuntary
thoughts and behavioral habits). Additional techniques
focus on body posture and a healthy lifestyle and on
handling the pain during an attack. Lesson 1 provides
an introduction, health education, and explanation of
the training goals. Lessons 2–4 aim at graded acquisi-
tion and practice of self-management skills, while les-
sons 5–7 focus on skill application in daily life. Lesson 8
summarizes the acquired skills, and contains the plan-
ning of skill maintenance and strategies for relapse pre-
vention. Each lesson takes approximately one hour to
complete, plus one to two hours for homework and
daily relaxation exercises (30 minutes in the ﬁrst and
10 minutes in the second half of oBT). Completion of
assignments within and between lessons was obligatory
in order to enter the next lesson (ascertained by a
‘‘selective release’’ function in the MyMigraine web-
portal). Participants were advised to complete each
lesson within seven to 10 days (12–15), but given the
mean training completion time (3.6 months; SD¼ 1.4
(24)) this took two weeks on average. A trained
postgraduate psychologist or master’s level psychology
student under supervision of a clinical psychologist pro-
vided the email support, which consisted of weekly
reminders, encouragement and tips (5 minutes) and
of assistance, motivational support, and concluding
comments upon completion of lessons 1–7 (10–15 min-
utes). Most participants (85%) preferred to be con-
tacted biweekly or only when completing a lesson.
The total time investment for support thus was 1.5
hours on average in most cases and two hours for
15% who preferred weekly contacts.
Measurements
The online headache diary was freely available, while
daily entries were required for 30 days at T0, T1 and
T2. Per day, headache occurrence could separately be
indicated for the morning, afternoon, evening, and
night, accompanied by intensity ratings on a visual
analog scale (VAS, range 0.1–10.0). ICHD-II character-
istics (26), and medication use for headache (yes/no),
could be ticked oﬀ. Yes for medications opened a per-
sonal list established at baseline for the marking of
agents used; administration quantities could be added
but this was not mandatory. Text boxes allowed regis-
tering new drugs and premonitory features of the attack;
women also logged their menstruation. Diary entries
took a few minutes, and were visually available in an
online migraine monitor (see online Supplementary
Material, part 1). The monitor showed the course of
headache in monthly graphs and distinguished the
migraine attacks as classiﬁed according to the ICHD-
II (26); symbols indicated the number of pharmaco-
logical agents used and the occurrence of menstruation
in women; clicking a day permitted review, but not revi-
sion, of all diary answers. A diary entry could represent
a day with or without headache; inclusion in the data
analysis required 25 entries per measure point.
Attacks had to fulﬁll the ICHD-II criteria (26,31) of
2 migraine characteristics (unilateral location, pulsat-
ing quality, moderate or severe intensity, aggravation
by physical activity) and 1 accompanying symptoms
(nausea and/or vomiting; photo- and phonophobia).
Attack frequency was counted, considering that recur-
rence within 48 hours from attack onset or within 24
hours after end of the attack covered one attack. For
headache top intensity we counted the number of ratings
with VAS pain intensity >7.0. Medications were classi-
ﬁed as triptans, analgesics and prophylactic agents. Use
of rescue medication was calculated separately for trip-
tans and analgesics by counting the number of head-
ache days each agent was taken (27).
Self-eﬃcacy was assessed with the Dutch translation
of the Headache Management Self-Eﬃcacy question-
naire (HMSE) (32) consisting of 25 items with answers
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ranging from 1 (absolutely disagree) to 7 (absolutely
agree). A higher score (range 25–175) indicates stronger
conﬁdence in one’s behavioral skills to prevent and
manage recurrent headaches.
Perceived control over migraine was assessed with the
Dutch translation of the Headache-Speciﬁc Locus of
Control Scale (HSLC) (33) reﬂecting the expectation
that the onset, course and severity of one’s migraine
can be inﬂuenced by one’s own actions (11 items),
fate/chance (11 items), or actions of medical profes-
sionals (11 items). Item responses range from 1 (strongly
disagree) to 5 (strongly agree) and higher scores indicate
more control. Because oBT was not designed to inﬂu-
ence trust in health care, we included the subscales for
internal (perceived self-control over migraine; range
11–55) and external LOC (the conviction that migraine
is a matter of fate or chance; range 11–55).
Migraine-speciﬁc quality of life was measured with
the Dutch version of the Migraine-Speciﬁc Quality of
Life questionnaire (MSQOL) (34) consisting of 20 items
with agreement scores ranging from 1 (very much) to 4
(not at all). A higher score reﬂects a better quality of life
between attacks (range 20–80).
Migraine-related disability was assessed with the
Dutch translation of the Migraine Disability
Assessment Scale (MIDAS) (35). For the past three
months the days lost – and those with 50% lost pro-
ductivity – due to headache, are assessed separately for
paid work and housework; for family, social and leisure
activities the days lost to headache are assessed as well.
The MIDAS score sums all missed days plus the days
with less than 50% productivity at work or at home.
Health care use was assessed at T0 and T2 with the
Trimbos and iMTA questionnaire for costs associated
with psychiatric illness (TiC-P) (36). We used 10 items
of part 1 for health care consumed in the preceding
month regarding consultations with a GP or a neurolo-
gist, use of mental, paramedic or alternative health ser-
vices, and hospital treatments or admissions.
Sample size
The sample size was grafted on migraine attack fre-
quency. An eﬀect size (ES) of 0.35 emerged for online
interventions in headache (16) and was proposed as a
benchmark for routine psychological treatments in
chronic pain (37). A power of 0.80 in two-tailed testing
with ES¼ 0.35 and ¼ 0.05 yielded N¼ 130 per group,
and 370 participants were needed, accounting for 30%
expected study attrition.
Statistical analyses
All analyses were based on the intention-to-treat
principle (ITT). We used multiple imputation for
handling missing data (38), employing a chain of
conditional regression models (fully conditional
speciﬁcation (FCS) (39)). Computations were carried
out separately per group by the package Mice (40) in
R (41), with 50 iterations for the algorithm to
converge and 100 multiply imputed datasets,
specifying the model type for scale variables as
predictive mean matching (PMM). The eﬀectiveness
outcomes of the 100 datasets were combined into
one single estimate using Rubin’s rules (38).
Cohen’s d (42) will indicate ES of the outcomes
within (baseline to T2) and between the groups at
T2 (negligible: d< 0.2, small: 0.2 d< 0.5, medium:
0.5 d< 0.8, large: d 0.8). Results are presented as
the mean and standard deviations of the observed
data; analyses are based on the imputed data with
p¼ 0.05 as cut-oﬀ for statistical signiﬁcance in two-
tailed testing.
Between-group diﬀerences in the change trajec-
tories per outcome measure were tested by a series
of individual growth curve (IGC) models using linear
mixed modelling (LMM) in SPSS with maximum
likelihood (ML) expectation. The ﬁrst step (uncondi-
tional model) established the intraclass correlation
(ICC) representing the amount of variance due to
diﬀerences between individuals. The next two steps
determined the shape of the growth, with step 3
depending on signiﬁcant results of time in step 2.
Step 2 tested linear growth by including time as a
predictor; in step 3 time2 was entered to examine
quadratic growth and, if so, detect acceleration or
deceleration over time. Step 4 included group and
time*group interactions to examine the diﬀerential
growth trajectories for oBT versus WLC. Initial
models were tested with the covariance structure
‘‘variance compound.’’ All analyses were repeated
with study completers only, and for log-transformed
data to correct for skewedness in the measurements
of analgesic use and migraine disability (sensitivity
analyses). These results did not lead to diﬀerent con-
clusions and are therefore not reported.
To explore reasons for attack reduction during the
waitlist phase, improvement was compared between
WLC participants who had used the migraine moni-
tor frequently (80% of the days) versus those who
had used it occasionally (20%) between T0 and T1
(mean 3.4 months; SD¼ 0.7). Also the WLC and
oBT condition were compared regarding health care
use prior to T2, and regarding extended medication
use established by the headache diary at T1 and at
T2. (We examined all changes in medications used for
headache. Extended use entailed that a participant
added a new medication category (triptans, analgesics
or prophylactics) or replaced an analgesic purchased
over the counter by an anesthetic that required
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medical prescription. Alterations of equivalent drugs
within categories were ignored.)
Results
Patient flow through the study and participant
characteristics
Figure 1 shows the ﬂow through the study of 368 ran-
domized participants (oBT: N¼ 195; WLC: N¼ 173)
consistent with the Consolidated Standards of
Reporting Trials (CONSORT) statement (43). Study
attrition was 24% from T0 to T1 (oBT: 32%; WLC:
14%) and 37% from T0 to T2 (oBT: 43%; WLC: 29%).
Among participants with known reasons for drop-out,
loss of interest occurred less in oBT (16%) than in
WLC (41%).
Table 1 shows that respondents had a mean age of 44
years (SD¼ 12), the majority were female (85%), mar-
ried (78%) and higher educated (65%), and they had
suﬀered from migraine for 22 years on average
(SD¼ 13). Few participants had formerly seen a psych-
ologist (16%), while most had sought medical advice
(GP: 93%; neurologist: 68%) and used rescue
medications for migraine (triptans: 80%; analgesics:
69%). Successful randomization was conﬁrmed by
absence of signiﬁcant between-group diﬀerences in base-
line characteristics (Table 1), health care use in the four
weeks preceding T0 (TiC-P, not in Table 1), and baseline
values of all outcome measures (Table 2).
Analyses of effectiveness
The results are organized by primary, secondary and
exploratory outcomes. Table 2 presents the observed
means at baseline (T0), post-treatment (T1), and six
months later (T2), while testing was based on the
imputed data (ITT). Figure 2 illustrates the change
over time in all parameters (for all p values and models
for individual growth see online Supplementary
Material, part 2).
Outcomes are grouped for migraine and rescue
medications (to the left), and for psychological change
relevant to self-management, and change in migraine
consequences (to the right).
oBT: online behavioral training in migraine self-
management; WLC: waitlist control; LOC: locus of
control.
Figure 1. Participant flow through the study.
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Primary outcomes. Table 2 shows that migraine attack
frequency decreased signiﬁcantly over time in oBT
(23%; ES¼ 0.66, p< 0.001), but this occurred with-
out signiﬁcant diﬀerence also in WLC. The change
trajectories in both groups yielded decreased attack
frequency over time (time: b¼5.2, p< 0.001) with
a steeper decrease between T0 and T1 (time2:
b¼ 5.6, p< 0.001). Positive change over time in
migraine self-eﬃcacy and LOC, however, occurred
only in oBT with small to medium ES (range
0.370.61, p< 0.001) and with similar values for the
diﬀerences between conditions (range 0.430.61,
p< 0.001). The growth analysis conﬁrmed diﬀerential
trajectories (Table 2, right columns) in favor of oBT,
where self-eﬃcacy and internal control increased and
external control decreased from T0 to T1 and then
remained stable.
Secondary outcomes. Over time headache top intensity
improved signiﬁcantly only in oBT (31%; ES¼ 0.24,
p¼ 0.032), but the growth analyses did not conﬁrm a
signiﬁcant decline over time. Triptan use, however,
decreased exclusively in oBT (16%; ES¼ 0.54,
p< 0.001), and the growth analysis substantiated the
signiﬁcant between-group eﬀect (b¼1.6, p¼ 0.001).
Use of analgesics (73% of which were mild anesthetics
purchased without medical prescription) remained
unchanged. Improved migraine-speciﬁc quality of life
reached a sizable eﬀect only in oBT (T2: ES¼ 0.47,
p< 0.001) approaching between-group signiﬁcance
(p¼ 0.051) but uncorroborated by the growth analysis.
Migraine disability improved in oBT (23%;
ES¼ 0.28, p¼ 0.009), but again without between-
group signiﬁcance.
Explorative analyses. Exclusion of participants who used
prophylactic medications as recommended for behav-
ioral research (8) did not aﬀect any of the outcomes.
A reduction 50% in attack frequency was adopted
as clinically signiﬁcant change or treatment responder
rate, in accordance with other studies (12,17,19,20,22).
Diﬀerences ranging from þ49% to 49% were con-
sidered no change, and an increase of 50% was
deemed an adverse response. Clinically signiﬁcant
change remained stable. At T2 oBT had 39% respon-
ders, 41% of the participants with no change, and
20% with an adverse response (for WLC this was,
respectively, 33%, 46% and 21%). In the WLC con-
dition attack improvement between frequent (N¼ 54)
and occasional (N¼ 48) users of the migraine monitor
did not diﬀer over time (p 0.31), nor was there evi-
dence that this group consumed more health care
prior to T2 regarding medical consultations of a GP
(WLC: 34%, oBT: 30%) or neurologist (WLC: 7%,
oBT: 8%), use of mental health care (WLC: 16%,
oBT: 14%), paramedic and alternative services
(WLC: 54%, oBT: 53%), and hospital treatments or
admissions (WLC: 1%, oBT: 2%).A small proportion of
participants extended their headachemedications during
the trial: 4% in oBT (T1: 2%, T2: 2%) and 7% in WLC
(T1: 5%, T2: 2%).
Discussion
This study showed that positive eﬀects of oBT on
migraine self-eﬃcacy and perceived control were sus-
tained over 10 months compared to WLC. However,
the improved self-management did not translate to
improved attack frequency since attacks decreased in
Table 1. Baseline characteristics of the participants.
oBT
(N¼ 195)
WLC
(N¼ 173)
Total
(N¼ 368)
Age, mean (SD) 43.0 (12) 44.3 (11) 43.6 (11.5)
Gender, N (%)
Male 26 (13) 28 (16) 54 (15)
Female 169 (87) 145 (84) 314 (86)
Educationa, N (%)
Low 5 (3) 3 (2) 8 (2)
Middle 62 (32) 59 (34) 121 (33)
High 128 (66) 111 (64) 239 (65)
Marital status, N (%)
Married 156 (80) 132 (76) 288 (78)
Single/divorced/widowed 39 (20) 34 (24) 73 (22)
Migraine duration
in years, mean (SD)
21.4 (13) 22.6 (13) 21.9 (13)
Self-reported aura, N (%)
Yes 74 (38) 53 (31) 127 (35)
No 102 (52) 98 (57) 200 (54)
Unknown 19 (10) 22 (13) 41 (11)
Migraine attack frequency, N (%)
Low 3 attacks 102 (52) 88 (51) 190 (52)
High >4 attacks 93 (48) 85 (49) 178 (48)
Medication use, N (%)
Triptans 162 (83) 133 (77) 295 (80)
Analgesicsb 142 (73) 111 (64) 253 (69)
Prophylactics 52 (27) 45 (26) 97 (26)
Consultations, N (%)
General practitioner 182 (93) 161 (93) 343 (93)
Neurologist 136 (70) 113 (65) 249 (68)
Psychologist 31 (16) 28 (16) 59 (16)
Physiotherapist 96 (49) 71 (41) 167 (45)
aLow: primary school or lower level vocational training; middle: sec-
ondary education or middle level vocational training; high: bachelor or
master’s degree.
bThe majority of analgesics (73%) were purchased over the counter
(OTC) and required no prescription. oBT: online behavioral training in
migraine self-management; WLC: waitlist control.
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both groups (oBT: –23%, ES¼ 0.66; WLC: 19%,
ES¼ 0.52). Of the secondary outcomes, triptan use
decreased signiﬁcantly in oBT (16%, ES¼ 0.54),
while it increased in WLC (þ5%, ES¼ 0.15). Other
between-group diﬀerences were not signiﬁcant, but it
remains noteworthy that only oBT yielded a sizable
improvement in migraine-speciﬁc quality of life
(ES¼ 0.47).
Attack frequency declined while in WLCs triptan use
increased to some extent, which could partly explain
attack improvement in this group. In oBT, however,
reduced attacks (23%) and parts of days with incapaci-
tating headache (31%) went along with decreased trip-
tan use. A diﬀerent process thus seemed to have occurred
in both conditions. The oBT group could have acquired
self-management to someextent – given their achievement
of migraine self-eﬃcacy and perceived control – as a new
tool to handle their migraine supplementary to rescue
medications.
Additional reasons must also be explored, however,
because the present attack improvement in WLCs vastly
exceeded the 4%–6% in waitlist groups of former (o)BT
studies (12,17,19,44,45), as well as placebo eﬀects of 9%–
10% in BT (44) or migraine rescue medications (46,47).
Our participants could have admitted at a time of tem-
porary migraine aggravation that decreased over time,
but our trial seemed equally prone to this phenomenon
as prior trials in (o)BT. The current WLC improvement
also is beyond what could be expected from
methodological artifacts such as random measurement
errors (48,49), and help seeking behavior was compared
but did not diﬀer between conditions. Episodic migraine
with 6 attacks per month has a relatively favorable
prognosis over >10 years (50), however; natural history
could thus have contributed but is unlikely to fully
account for a remission of 19% of the attacks over 10
months’ time (46,50).
We excluded the explanation of high monitor use
between the end of T0 and start of T1 when diary keep-
ing was optional, but access to the migraine monitor
may still have been a factor. The MyMigraine portal,
migraine monitor and training were very well received
(30); therefore reinforcement through this monitor may
account for the limited study attrition in WLCs (T1:
14%; T2: 29%). But monitoring per se is not assumed
to have induced self-management, because the WLC
group gained neither self-eﬃcacy nor a sense of control
in migraine management.
Strengths and limitations
A predominant strength of this study is the extended
follow-up with two post-training measure-points, which
also applied to a previous controlled oBT study in
adults during which eﬀects on migraine were not
assessed, however (23). Other strengths include the
use of a prospective diary to sample migraine attacks
according to the ICHD-II, and a training protocol
Figure 2. Change over time in all outcome measures.
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rated by the participants as intelligible, instructive,
important and not too diﬃcult to accomplish (30).
Last, we carefully selected a large sample of patients
who had sought former medical advice (GP: 93%;
neurologist: 68%), used valid medications for migraine,
and only marginally extended this use during the trial
(oBT: 4%; WLC: 7%). This indicates that our sample
was medically informed and represented migraine
patients under adequate treatment as usual.
High attrition typically hampers Internet-based
trials (51), particularly in early studies including those
for headache (16,17,19). In the present study failure to
keep the online headache diary on 25 of 30 days
per measure-point counted as study attrition.
Notwithstanding this stringent criterion our attrition
rates were not excessive (T1: 24%, T2: 37%), matching
those of oBT trials in headache with an extended
follow-up (T1: 24%, 14%; T2: 38%, 33%) (21,23)
and 27% mean post-treatment attrition of web-based
trials in chronic pain (52); also multiple imputation
techniques counteracted the potential bias due to miss-
ing data. Second, we would have preferred number of
administrations per headache drug as the measure for
rescue medications, but this rating was not mandatory
in our headache diary (this will be adapted). We com-
pared results for the number of days a certain agent was
taken (reported) with those for the number of admin-
istrations used. But given the incomplete data for
administrations, our ﬁnding that these results were
highly comparable must be interpreted with caution.
Third, we chose to interfere as little as possible with
the waitlist group and thus did not assess their treat-
ment expectation or responses to our portal and tools,
but such assessments would have helped to understand
the attack improvement in WLC. Likewise, measure-
ments of continued self-management and usage of stra-
tegies for relapse prevention were not performed in the
oBT group. Both types of assessments should be con-
ducted in future research.
Outlook on longer-term gains and future research
BT eﬀects are known to develop gradually but to be dur-
able (15,25,53). In this study the oBT eﬀects on migraine
tended to increase from T1 to T2, also relative to WLC
(see Figure 2), and this trend could continue over time.
Whether oBT induced additional attack improvement in
the presentWLCgroupwill appear from the results—not
as yet available—of oBT oﬀered toWLC after T2, again
with two follow-up measurements. The perspective on
durable oBT gains is supported by the similarity in par-
ticipant characteristics, training protocol, and training
eﬀects in the current and the previous study (see online
Supplementary Material, part 3), eﬀects of which were
maintained for three years (15).
Our WLC assessment showed that longitudinal, pro-
spective monitoring is feasible in migraine with limited
attrition. This is important in its own right, because not
much is known about ﬂuctuations in migraine attack fre-
quency over time. Future research should comprise such
prospective assessments, in order to disseminate the
impact of natural course, medication change, and behav-
ioral or contextual factors onmigraine attack occurrence.
Last, eﬀorts to decrease attrition rates are of utmost
importance. One oBT study in headache (22) stood out
with lower rates (of 12% and 20% according to our
calculation) at, respectively, three and six months
after the start of training. The authors underscored
two important reasons: (1) a compulsory headache
diary that allowed a new entry only when data for the
previous day were available, and (2) thorough face-to-
face contact with all participants at the time of inclu-
sion. The eﬀect of both of these arrangements should be
clariﬁed in future research.
Conclusions
This study could not corroborate that the improvement
in migraine attack frequency over 10 months’ time was
due to oBT, as the WLC group progressed too.
However, only oBT had sustained eﬀects on migraine
self-eﬃcacy and perceived control, which indicate
better migraine self-management. Whether oBT adds
to the prevention of migraine attacks still has to be
established. This deserves further study because BT has
fewer side eﬀects compared to medications (25), and
because the online provision of BT can increase BT out-
reach as well as improve its cost-eﬀectiveness.
Clinical implications
. Behavioral training (BT), based on techniques of cognitive-behavioral therapy including relaxation training,
can contribute to attack prevention in migraine.
. Online provision of this training (oBT) can increase BT outreach and improve the cost-eﬀectiveness of BT.
. This study showed that attack improvement after oBT was not superior to waitlist controls of patients under
treatment as usual who were followed with an online diary with visual feedback. However, signiﬁcant
indications of improved self-management and decreased triptan use occurred only when oBT was oﬀered.
. BT outreach can be improved via patient trainers, the Internet, and – potentially – a combination of both
settings.
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